SCHEMBL2130061

SCHEMBL2130061

Clc1ccc(C2O[C@@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@H](OCc3ccccc3)[C@H]2OCc2ccccc2)cc1CBr

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.41
▸ SSTR1 P30872 1/20 0.39
▸ SSTR2 P30874 1/20 0.39
▸ SSTR4 P31391 1/20 0.39
▸ SSTR3 P32745 1/20 0.39
▸ SSTR5 P35346 1/20 0.39
▸ PTPN1 P18031 8/20 0.39
▸ CDC25B P30305 8/20 0.39
▸ PTPN2 P17706 4/20 0.39
▸ PTPN6 P29350 4/20 0.39
▸ PTPN11 Q06124 4/20 0.39
▸ SLC5A2 P31639 1/20 0.39
▸ NT5E P21589 1/20 0.39
▸ BCHE P06276 2/20 0.38
▸ ACHE P22303 1/20 0.37
▸ TACR2 P21452 1/20 0.37
▸ GJB2 P29033 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830061 1.00 HTR1A (0.41) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL15610303 1.00 HTR1A (0.41) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL20643059 0.89 PTPN1 (0.43) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL9986268 0.89 PTPN1 (0.43) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL2131297 0.89 PTPN1 (0.43) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL9986263 0.89 PTPN1 (0.43) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL15610890 0.89 PTPN1 (0.43) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL2460275 0.89 SLC5A2 (0.48) SLC5A2GJB2
SCHEMBL20643029 0.87 SSTR1 (0.41) HTR1ASSTR1SSTR2SSTR4SSTR3
SCHEMBL2133682 0.87 PTPN1 (0.43) HTR1APTPN1CDC25BPTPN2PTPN6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541380-B2 C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same GREEN CROSS CORPORATION (KR) 2013-09-24 — — US disclosed
US-20120101051-A1 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME GREEN CROSS CORPORATION (KR) 2012-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101051-A1 NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME SLC5A2, SLC5A1, SLC2A2 HTR1A 3046/4885SSTR1 2149/4885SSTR2 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback